CVC  Astellas Venture Management

     Office Locations:

PO Box 7585
Menlo Park, CA 94026



  • Early
  • Expansion
  • Seed



  • Life Sciences & Healthcare



    Originally established in 2000 as Yamanouchi Venture Capital, Astellas aims to reinforce Astellas Pharma's assets by supporting companies that can become Astellas Pharma's collaboration partners in R&D. Astellas Venture invests in companies that are dedicated to: developing new pharmaceutical seeds, or constructing a new drug discovery platform. In addition to the disease area of Urology and Inflammation/Immunology, Astellas has an interest in the fields of CNS, Pain, Diabetes/Metabolic disease, Anti-infectives (anti-viral) and Cancer. Astellas is active mainly in seed and early-stage investments in companies that have not yet begun testing their products in clinical trials, as well as firms that have programs at very early stages of clinical trials. However the firm also considers participating in expansion-stage investments. Astellas' investments range in size from $.5 - 10 million. Initial investments typically range from $.5 - 2 million. The venture group is a division of Astellas Pharma, Inc., a Tokyo based company created in 2005 by the merger of Yamanouchi Pharmaceutical Co., Ltd. and Fujisawa Pharmaceutical Co., Ltd. AVM manages the following funds: AVF I (Astellas Venture Fund I), AVC (Astellas Venture Capital), FITE (Fujisawa Investments for Entrepreneurship), and FITE II (Fujisawa Investments for Entrepreneurship II).

    Investment Firm Key

       VC = Venture Capital
       PE = Private Equity
       A = Angel
       I = Incubator
       MB = Merchant Bank
       VD = Venture Debt
       FI = Family Investment Office
       FOF = Fund of Funds
       ED = Economic Development Office   
       TT = Technology Transfer Office
       CVC = Corporate Venture Capital
       SEC = Secondary Purchaser
       HF = Hedge Fund/Mutual Fund
    Venture Capital
    Seed Stage
    (includes "pre-seed," or
    concept stage)
    No Revenue
    Early StageMinimal
    Growth Stage
    (also called Mid-stage)
    Expansion Stage
    (also called Late-stage)
    $7M and greater
    Private Equity
    Lower Middle Market$10M-$249M
    Middle Market$250M-$499M
    Upper Middle Market$500M-$1B
    Large Cap>$1B

    Investment Team:

    Name   Title
    Get the complete investment team + individual email addresses for investment team partners. Get personal images, LinkedIn links, investment specialties, office locations and more with a National Database subscription or Silicon Valley Database subscription.
    Kenichiro Shimokawa Ph.D. Senior Investment Director
    Makoto Ohori Ph.D. Investment Director
    Sakae Asanuma President & Chief Executive Officer


    Recent Funding Events (trailing 12 months):







      Orna Therapeutics



      Series A


    Portfolio companies include:


    Recent News: